At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study to Evaluate Neuropsychological Outcome Measures and Their Relationship With Prognosis in Patients Receiving Radiation Therapy for Brain Metastases
In Brief
An observational study for Brain Metastasis and Cancer. Completed, enrolled 35 participants across 1 site.
Signals
Detailed Summary
Background: * There are no standardized sets of tests to measure changes in neuropsychological functioning in patients treated for brain metastasis (cancer that has spread beyond the original site to the brain). * Neuropsychological function has an important effect on quality of life and should be included when determining treatment options. Objectives: * To find out if there is a change in patients cognitive (thinking) and daily functioning after standard radiation treatment for brain metastasis that can be measured with tests. * To see if any changes on these tests are related to patients response to radiation therapy. Eligibility: \- Patients 18 years of age or older who have cancer that has spread to the brain. Design: * Patients receive a 2-week course of radiation therapy to the brain, given daily 5 days a week. Some patients may require stereotactic radiosurgery (an additional boost of radiation therapy to specific sites of brain metastasis). * Patients have the following evaluations before and after treatment to determine changes in cognition and functioning: * Neuropsychological testing to measure cognitive (thinking) abilities like memory, attention, processing speed, and reading, and fine motor skills. * Questionnaires to assess quality of life and daily living skills. * Patients have MRI scans and blood and urine tests. * At the completion of radiation treatment, patients return to the clinic for follow-up visits at 1, 2, 4, 6, 9 and 12 months for blood and urine tests, physical examination, MRI of the brain, neuropsychological testing and assessments of quality of life and daily living skills.
Study Details
Timeline
Arms & Interventions
KPS\>70; Age =65; controlled primary tumor and no extracranial metastases
KPS\>70 and at least one of the following: age \>65, uncontrolled or synchronous primary disease, or extracranial metastases
KPS\<70